Company History

Founded in 1996 in Sweden as Cortendo AB, our original focus was on regulating cortisol secretion in patients with diabetes.

In the course of reinventing, refocusing, and reinvigorating the company, Strongbridge Biopharma has reached a series of pivotal business and clinical milestones.

2016: An Important Year for Strongbridge

In December 2016, Strongbridge Biopharma acquired the US rights to KEVEYIS® (dichlorphenamide). This acquisition is part of our commitment to expand our portfolio and help meet the needs of patients with rare and orphan diseases that are underdiagnosed and undertreated.

Key Milestones

Recent clinical milestones reflect our focus on rare diseases and our organizational agility in meeting the challenges of drug development.

Jul 2017

Last patient enrolled (LPI) in phase 3 SONICS trial of RECORLEV (levoketoconazole) for endogenous Cushing's syndrome

Dec 2016

Acquired KEVEYIS (dichlorphenamide) from Taro Pharmaceutical Industries for Primary Periodic Paralysis

Jun 2015

Acquired veldoreotide, being studied for acromegaly, from Aspireo Pharmaceuticals

Aug 2014

First patient enrolled in phase 3 SONICS trial of RECORLEV in endogenous Cushing's syndrome

Aug 2012

RECORLEV received EU orphan drug designation

Mar 2012

RECORLEV received US orphan drug designation

Feb 2012

Pivoted RECORLEV focus from diabetes to Cushing's syndrome

Please see KEVEYIS Important Safety Information and Full Prescribing Information.

Learn more about our investigational therapies

RECORLEV (levoketoconazole) and veldoreotide

© 2017 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA is a trademark of Strongbridge Biopharma plc.
KEVEYIS® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V11 10/2017

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200
info@strongbridgebio.com

Privacy Statement
Comprehensive Compliance Program
California Statement of Compliance